Salarius Pharmaceuticals

Salarius Pharmaceuticals

HQ
Houston, TX
20 Total Employees
Year Founded: 2011

Jobs at Similar Companies

Similar Companies Hiring

Software • Pharmaceutical • Manufacturing • Healthtech • Biotech • Analytics
4 Offices
50000 Employees
Software • Pharmaceutical • Machine Learning • Biotech • Big Data • Artificial Intelligence • Analytics
11 Offices
63000 Employees
Telehealth • Social Impact • Pharmaceutical • Healthtech
Miami, FL
13 Employees

Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing cancer therapies for patients in need of new treatment options. Salarius’ product portfolio includes seclidemstat, a reversible LSD1 inhibitor, which is being studied as a potential treatment for pediatric cancers, sarcomas, and other cancers with limited treatment options, and SP-3164, an oral small molecule targeted protein degrader. Seclidemstat is currently in a Phase 1/2 clinical trial for relapsed/refractory Ewing sarcoma and select additional sarcomas that share a similar biology to Ewing sarcoma, also referred to as Ewing-related or FET-rearranged sarcomas. Seclidemstat has received Fast Track Designation, Orphan Drug Designation, and Rare Pediatric Disease Designation for Ewing sarcoma from the U.S. Food and Drug Administration. Salarius is also exploring seclidemstat’s potential in several cancers with high unmet medical need, with a second Phase 1/2 clinical study in hematologic cancers, initiated by MD Anderson Cancer Center. Salarius has received financial support from the National Pediatric Cancer Foundation to advance the Ewing sarcoma clinical program and was also a recipient of a Product Development Award from the Cancer Prevention and Research Institute of Texas (CPRIT). For more information, please visit salariuspharma.com or follow Salarius on Twitter and LinkedIn.


Salarius Pharmaceuticals Offices

OnSite Workspace

Employees work from physical offices.

Typical time on-site: None
HQHouston, TX